Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
NEWARK, Calif., Feb. 23, 2016 -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will be participating in two upcoming investor conferences.
Revance management is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA on Tuesday, March 8 at 10:00am ET.
Revance management is also scheduled to present at the Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 15 at 11:15am ET.
Interested parties can access the live audio webcast for both of these conference presentations from the investor relations section of the company’s website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin drug products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a targeted and potentially long-lasting delivery. Revance is pursuing clinical development for drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001) and DaxibotulinumtoxinA RT002 for Injection (RT002), in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at www.revance.com.
"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Contacts Investors: Revance Therapeutics Jeanie Herbert (714) 325-3584 [email protected] Westwicke Partners Leigh Salvo (415) 513-1281 [email protected] Trade Media: Nadine Tosk (847) 920-9858 [email protected]
